Clinical Trials Logo

Filter by:
NCT ID: NCT04554563 Completed - Low Back Pain Clinical Trials

The Effect of Core Stability Training on Deep Stabilizing Muscles.

Start date: September 12, 2020
Phase: N/A
Study type: Interventional

Non-specific low back pain is the most cause of adult disability throughout life. Its prevalence widens in young adults. Background of this pathology can be multifactorial. One of the most common is poor core stability and overloading of the local tissues as a result. Among treatment methods stabilizing training is commonly used with good effects. This form of therapy affects the transverse abdomen and multifidus muscles. To assess these structures several methods can be applied, e.g. sonofeedback. Our hypothesis claims that the core muscles morphology will change over the training process duration, in result, the analgesic effect will be achieved.

NCT ID: NCT04546425 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

NCT ID: NCT04545580 Completed - Overactive Bladder Clinical Trials

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)

OVADER
Start date: September 16, 2020
Phase: Phase 2
Study type: Interventional

The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling desire to void. BAY1817080 is a new drug under development which blocks proteins expressed on the sensory nerves in the bladder. These nerves seem to overreact in OAB patients. This study will test if the treatment with BAY1817080 will reduce the frequency of OAB symptoms. The frequency of OAB symptoms before the treatment and the frequency after 4, 8 and 12 weeks of treatment will be compared. Another important objective of this study will be the assessment of BAY1817080 safety and tolerability in this patient population. BAY1817080 will be compared to a "placebo". A placebo tablet looks like the study drug but does not have any medicine in it. Using a placebo helps to learn if the study drug works. Each participant is expected to take part in the study for about 5 months (around 20-22 weeks).

NCT ID: NCT04542499 Completed - Parkinson Disease Clinical Trials

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

TEMPO-3
Start date: October 27, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.

NCT ID: NCT04542057 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Start date: September 22, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT04541498 Completed - Clinical trials for Cardiovascular Diseases

Impact of Air Pollution and Climate Changes on the Epidemiology of Cardiovascular Disease

PL-PARTICLES
Start date: January 1, 2019
Phase:
Study type: Observational

Despite the fact that the topic of air pollution has been in focus of researchers for many years, there are no big studies that take up the matter of its influence on acute coronary, cerebral syndromes and CVD mortality in Europe. Taking into consideration the scarce number of surveys from Europe the investigators decided to analyze the impact of air pollution on cardiovascular diseases and CVD mortality in Poland.

NCT ID: NCT04541186 Completed - Clinical trials for Severe Hypertriglyceridemia

Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (QW or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 compared to placebo in subjects with Severe Hypertriglyceridemia (SHTG).

NCT ID: NCT04539925 Completed - Clinical trials for Acute Coronary Syndrome

Air Pollution Exposure on Acute Coronary Syndrome in Two Cohorts of Industrial and Non-industrial Areas

Start date: December 1, 2019
Phase:
Study type: Observational

Background: There is a lack of data on the effect of air pollution on acute coronary syndrome (ACS) in industrial and non-industrial areas. Objectives: A comparison of association of air pollution exposure with ACS in two cohorts of industrially different areas. Materials and methods: The study covered 6,000,000 person-years of follow-up and five types of air pollution between 2008 and 2017. A time series regression analysis with 7-lag was used to assess the effects air pollution on ACS.

NCT ID: NCT04537507 Completed - Clinical trials for Coronary Artery Disease

Atrial Fibrillation and Non-obstructive Coronary Lesions

AF-CAD
Start date: January 2010
Phase:
Study type: Observational

Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with excessive risk of ischemic stroke and heart failure as well as reduced life expectancy. On the other hand, chronic coronary syndromes (CCS) remains the main cause of morbidity and mortality in an aging population. Both disease entities share common risk factors such as hypertension, diabetes and obesity The purpose of the study is to investigate the hypothesis indicating lack of significant coronary lesions in AF vs. sinus rhythm (SR) patients.

NCT ID: NCT04535986 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Start date: September 29, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).